Thirty cases were treated. Of them, 2 were basically cure, 8 remitted, 14 remarkably ameliorated, 6 cases ineffective, the total effective rate being 80%. Changes in signs and symptoms revealed that the rate of amelioration was over 75%. After the therapy, the values of CD3, CD4, and CD4/CD8 were all markedly increased, CD8 markedly lowered with significant statistic differece (P

Objective To evaluate haematogenesis of complex Shenlu granule in treating myelodysplastic syndrome (RA/RCMD) due to kidney yang deficiency. Methods The qualified cases were randomly divided into the complex Shenlu granule group and the Andriol group. During treatment, indexes such as peripheral hemogram, T cell subgroup, NK cell and immunological phenotypic expression of BMC were tested. Results Compared with prior treatment, Rbc, Hb and Plt have significantly increased in Shenlu group [prior treatment: (2.39±0.99)×1012/L, (84.47±28.68) g/L, (81.13±96.85) ×109/L; post-treatment (2.80±0.98)×1012/L, (94.87±25.63) g/L, (98.67±107.9)×109/L, and the difference was statistically significant (t =4.0359, P =0.001, t =2.7009, P =0.0172, t =2.2573, P = 0.0405). Andriol group has only increased Hb [prior treatment: (71.93±27.53) g/L; post-treatment (80.07±26.03) g/L] was statistically significant (t =2.3125,P =0.0365). After treatment, CD+4, CD+8, CD+4/CD+8, and NK were at or near normal value in Shenlu group (37.9±5.9) %, (24.0±5.8) %, 1.75±0.83, (13.0±6.9) %, compared with prior treatment (29.3±11.7) %, (29.6±5.8) %,1.12±0.59, (8.8±5.7) %. The difference was statistically significant (t =2.6194, P =0.0202, t = 2.6595, P =0.0187,t =2.6581, P =0.0187, t =2.2288, P =0.0427, P <0.05), and CD+8, CD+4/CD+8 close to normal in Andriol group [(22.1 ±7.5) %, 1.50±0.74], prior treatment [(26.6±7.5) %, 1.18±0.55]. The difference was statistically significant (t =2.2377, P =0.0420, t =2.9352, P =0.0109, P <0.05). After treatment, CD+4 [Shenlu group:(37.9±5.9) %, Andriol group: (30.5±12.6) %] difference was statistically significant (t =2.1738, P =0.0474) in two groups; Shenlu group control abnormal expression of bone marrow cells, which were CD+13, CD+33, CD+34, CD+64,CD+117. The effect was better than Andriol group (the first three: u =2.76, u =3.39, u =2.85, P <0.01, the latter two: u =2.17, u =2.46, P <0.05). Conclusion clomplex Shenlu granule can effectively control normal hematopoietic function for MDS (RA/RCMD) due to kidney Yang deficiency.

Objective To observe the clinical efficacy ofFufang Shenlu Granule for kidney-yang deficiency aplastic anemia (AA) and its effects on CD4+ T lymphocyte subsets, and explore its mechanism.Methods Forty AA patients were randomly divided into treatment group and control group, 20 cases in each group. The treatment group was treated withFufang Shenlu Granule combined with conventional western medicine therapy, while the control group was only treated with conventional western medicine therapy. The treatment lasted for 6 months, and follow-up visits lasted for at least one year. The clinical efficacy and T lymphocyte subsets ratio changes before and after treatment in the two groups were observed.Results The clinical efficacy of treatment group was better than that of control group (P<0.05). After treatment, the blood cell counts of the two groups were improved than those of before treatment (P<0.05,P<0.01). After treatment, the red blood cell count and hemoglobin of treatment group were higher than those of control group (P<0.05). Compared with the data before treatment in treatment group, the ratio of CD4+CD25+ cells in all CD4+ cells, and the ratio of CD4+CD25+FoxP3+ cells in all CD4+CD25+ cells increased (P<0.05); the ratio of Th1 and Th2 cells in all CD3+CD4+ decreased (P<0.05). The ratio of Th2 cells was lower than that before treatment in the control group (P<0.05).ConclusionFufang Shenlu Granule can enhance the treatment efficiency of AA with kidney-yang deficiency syndrome. The mechanism may be related to the decrease of Th1 cells, the increase of CD4+CD25+Tregs and their FoxP3 expression.